PriceTargets.com logo

Dianthus Therapeutics - DNTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $42.40
  • Forecasted Upside: 97.21%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$21.50 As of 04/26/2024 01:00 AM ET
▲ +0.51 (2.43%)

This chart shows the closing price for DNTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dianthus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNTH

Analyst Price Target is $42.40
▲ +97.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $42.40, with a high forecast of $51.00 and a low forecast of $33.00. The average price target represents a 97.21% upside from the last price of $21.50.

This chart shows the closing price for DNTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Dianthus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2024Raymond JamesBoost TargetOutperform ➝ Outperform$34.00 ➝ $51.00Low
3/22/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$22.00 ➝ $39.00Low
3/22/2024WedbushBoost TargetOutperform ➝ Outperform$24.00 ➝ $33.00Low
2/15/2024Stifel NicolausInitiated CoverageBuy$44.00Low
1/26/2024WedbushBoost TargetOutperform ➝ Outperform$23.00 ➝ $24.00Low
12/26/2023Jefferies Financial GroupInitiated CoverageBuy$22.00Low
11/22/2023WedbushInitiated CoverageOutperform$23.00Low
10/30/2023GuggenheimInitiated CoverageBuy$45.00Low
9/28/2023Raymond JamesInitiated CoverageOutperform$24.00Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Dianthus Therapeutics logo
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Read More

Today's Range

Now: $21.50
Low: $20.69
High: $21.80

50 Day Range

MA: $25.66
Low: $20.99
High: $31.94

52 Week Range

Now: $21.50
Low: $6.58
High: $33.77

Volume

76,268 shs

Average Volume

168,520 shs

Market Capitalization

$631.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Dianthus Therapeutics?

The following Wall Street analysts have issued research reports on Dianthus Therapeutics in the last year: Guggenheim, Jefferies Financial Group Inc., Raymond James, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for DNTH.

What is the current price target for Dianthus Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Dianthus Therapeutics in the last year. Their average twelve-month price target is $42.40, suggesting a possible upside of 97.2%. Raymond James has the highest price target set, predicting DNTH will reach $51.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $33.00 for Dianthus Therapeutics in the next year.
View the latest price targets for DNTH.

What is the current consensus analyst rating for Dianthus Therapeutics?

Dianthus Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DNTH will outperform the market and that investors should add to their positions of Dianthus Therapeutics.
View the latest ratings for DNTH.

What other companies compete with Dianthus Therapeutics?

Other companies that are similar to Dianthus Therapeutics include Bicycle Therapeutics, Nurix Therapeutics, Evolus, Silence Therapeutics and Y-mAbs Therapeutics. Learn More about companies similar to Dianthus Therapeutics.

How do I contact Dianthus Therapeutics' investor relations team?

Dianthus Therapeutics' physical mailing address is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . The company's listed phone number is 857-242-0170 and its investor relations email address is [email protected]. The official website for Dianthus Therapeutics is dianthustx.com. Learn More about contacing Dianthus Therapeutics investor relations.